EDEN IAS

NEWS IMPULSE | VIRAFIN| 26 APRIL

Syllabus Section: Science and Technology

Why in News?

  • Drug Controller General of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms.

About:

  • Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, resulted in their faster recovery.
  • The studies confirmed the safety, tolerability and efficacy of Virafin.
  • The studies also reported that Viarfin reduces viral load and aid in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels.
  • About Zydus Cadila: Also known as Cadila Healthcare Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat.

Source: PIB

Chat With Us